Founded in 2005, Cellphire, Inc. is a pioneering company in commercial physical and biological research and development. The core mission of Cellphire Therapeutics is to save lives by introducing innovative hemostatic products to patients in critical need. Their primary products, currently in Phase 2 clinical studies, include the freeze-dried platelet-derived hemostat "FPH" (Thrombosomes®), which offers significant advantages over traditional liquid-stored platelets, such as longer shelf life and improved safety and efficacy.

Notable affiliated individuals include key researchers and industry experts who have driven the company's advancements in hemostatic technology. Cellphire has garnered attention from investors focused on groundbreaking medical solutions. The company's achievements include progressing their products through significant clinical trial phases, showcasing their potential to revolutionize emergency and surgical care. Overall, Cellphire's impact lies in its potential to enhance patient outcomes and address critical challenges in medical treatment.